EyePoint Pharmaceuticals Inc (EYPT)
8.68
-0.07
(-0.80%)
USD |
NASDAQ |
Jun 28, 16:00
8.69
+0.01
(+0.12%)
After-Hours: 20:00
EyePoint Pharmaceuticals Research and Development Expense (TTM): 81.18M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 81.18M |
| December 31, 2023 | 64.66M |
| September 30, 2023 | 62.25M |
| June 30, 2023 | 56.05M |
| March 31, 2023 | 53.32M |
| December 31, 2022 | 49.64M |
| September 30, 2022 | 43.02M |
| June 30, 2022 | 40.35M |
| March 31, 2022 | 32.97M |
| December 31, 2021 | 28.50M |
| September 30, 2021 | 24.79M |
| June 30, 2021 | 20.38M |
| March 31, 2021 | 18.05M |
| December 31, 2020 | 17.42M |
| September 30, 2020 | 16.35M |
| June 30, 2020 | 15.74M |
| March 31, 2020 | 16.42M |
| December 31, 2019 | 15.37M |
| September 30, 2019 | 17.47M |
| June 30, 2019 | 18.75M |
| March 31, 2019 | 18.12M |
| September 30, 2018 | 18.59M |
| June 30, 2018 | 16.18M |
| March 31, 2018 | 15.63M |
| December 31, 2017 | 15.62M |
| Date | Value |
|---|---|
| September 30, 2017 | 14.52M |
| June 30, 2017 | 14.88M |
| March 31, 2017 | 14.77M |
| December 31, 2016 | 14.52M |
| September 30, 2016 | 15.08M |
| June 30, 2016 | 14.38M |
| March 31, 2016 | 13.48M |
| December 31, 2015 | 13.74M |
| September 30, 2015 | 12.79M |
| June 30, 2015 | 12.09M |
| March 31, 2015 | 11.20M |
| December 31, 2014 | 10.13M |
| September 30, 2014 | 9.853M |
| June 30, 2014 | 9.573M |
| March 31, 2014 | 9.587M |
| December 31, 2013 | 8.905M |
| September 30, 2013 | 7.986M |
| June 30, 2013 | 7.005M |
| March 31, 2013 | 6.095M |
| December 31, 2012 | 6.016M |
| September 30, 2012 | 6.433M |
| June 30, 2012 | 7.039M |
| March 31, 2012 | 7.48M |
| December 31, 2011 | 7.709M |
| September 30, 2011 | 7.251M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
15.37M
Minimum
Dec 2019
81.18M
Maximum
Mar 2024
35.47M
Average
28.50M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Nanoviricides Inc | 7.168M |
| Bio-Path Holdings Inc | 9.907M |
| GlycoMimetics Inc | 20.68M |
| Ocular Therapeutix Inc | 67.04M |
| Aileron Therapeutics Inc | 5.644M |